Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
—
-117.85%
40%
—
—
40%
—
5 Years
Score—
Net Growth-117.85%
Net Trend40%
Net Income Consistency—
Rev Growth—
Rev Trend40%
Revenue Consistency—
Monte Rosa Therapeutics Inc fundamental performance
Across Monte Rosa Therapeutics Inc's full reported history, from 2021 to 2025, revenue grew from $ 0.00 to $ 123M and net income went from -$ 73M to -$ 38M. Revenue increased in 40% of the years measured; net income in 40%.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 15.95 | — |
1 Year2025-08-12 | $ 4.45 | 258.43% |
5 Years2021-08-12 | $ 32.24 | -50.53% |
All Time2021-06-24 | $ 21.18 | -24.69% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2021-06-24 |
|---|---|---|---|---|
| Price | $ 15.95 | $ 4.45 | $ 32.24 | $ 21.18 |
| Return | — | 258.43% | -50.53% | -24.69% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 28M | -$ 161M | $ 621M |
| 2025 | $ 123M | -$ 38M | $ 377M |
| 2024 | $ 75M | -$ 72M | $ 372M |
| 2023 | $ 0.00 | -$ 135M | $ 232M |
| 2022 | $ 0.00 | -$ 108M | $ 262M |
| IPO2021 | $ 0.00 | -$ 73M | $ 346M |
Explore beyond GLUE
You're looking at Monte Rosa Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
